Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Post Hoc Analysis: Time-From-Diagnosis Subgroups

When Used Within 6 Months of Diagnosis, There Was a 55% Relative Risk Reduction of Disease Progression With UPTRAVI® vs Placebo1

In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 55% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED WITHIN 6 MONTHS OF DIAGNOSIS VS PLACEBO1*

Time to first disease progression event in patients treated within 6 months of PAH diagnosis
Percent of patients treated within 6 months of PAH diagnosis without an event mobile curve
55% risk reduction HR 0.45 (95% CI: 0.33, 0.63)

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 35% (n=404) of all patients in GRIPHON were treated ≤6 months from diagnosis (52% FC II and 46% FC III)
  • 41% were receiving PDE-5i monotherapy, 39% were receiving no background PAH therapy, 10% were receiving ERA monotherapy, and 10% were receiving an ERA + PDE-5i at baseline
  • Mean age: UPTRAVI® (44 years), placebo (44 years)
  • FC II: UPTRAVI® (55%), placebo (49%)

Summary of primary endpoint events in patients treated within 6 months of PAH diagnosis

Events in patients treated within 6 months of PAH diagnosis mobile table

Adverse reactions in ≤6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%

Adverse reactions in ≤6 months from diagnosis subgroup notably different from overall population mobile table

The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.

In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 26% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED AFTER 6 MONTHS OF DIAGNOSIS VS PLACEBO1*

Time to first disease progression event in patients treated after 6 months of PAH diagnosis
Percent of patients treated after 6 months of PAH diagnosis without an event mobile curve
26% risk reduction HR 0.74 (95% CI: 0.57, 0.96)

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 65% (n=752) of all patients in GRIPHON were treated >6 months from diagnosis (56% FC III, 42% FC II)
  • 28% were receiving PDE-5i monotherapy, 11% were not receiving PAH background therapy, 17% were receiving ERA monotherapy, and 45% were receiving an ERA + PDE-5i at baseline
  • Mean age: UPTRAVI® (50 years), placebo (50 years)
  • FC II: UPTRAVI® (44%), placebo (41%)
Summary of primary endpoint events in patients treated after 6 months of PAH diagnosis
Events in patients treated within and after 6 months of PAH diagnosis mobile table

Adverse reactions in >6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%

Adverse reactions in >6 months from diagnosis subgroup notably different from overall population mobile table

The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.